ABSTRACT Background: Environmental enteropathy (EE) impairs the gut's absorptive capacity and immune function and causes decelerations in statural growth that manifest gradually over time. Objective: To illustrate an approach for assessing emerging biomarkers of EE, we separately assessed the associations between 3 such markers and subsequent nutritional status.
INTRODUCTION
Environmental enteropathy (EE) is increasingly understood as a critical pathway that mediates the interaction between nutritional status and immune response to infections (1) . For children raised in conditions of poor sanitation, environmental exposure to enteric pathogens starts early in infancy and occurs continually thereafter, putting the gut in a perpetual state of low-level T cell-mediated inflammatory immune stimulation (1) (2) (3) . Over time, this process disrupts normal intestinal function, altering the structure of the mucosal lumen surface and compromising the capacity of the gut to absorb available nutrients (2, 4, 5) . As the intestinal epithelium is rendered permeable to luminal contents, already depleted nutrient reserves are diverted away from investment in growth toward the mounting of systemic responses to translocated microbes (1) (2) (3) (4) . Subclinical self-limiting enteric infections may establish themselves more readily in outwardly asymptomatic EE-affected infants, with a cumulative impact that manifests only later as a deceleration in statural growth (2, 3, (5) (6) (7) .
Because growth faltering starts early in life, there is a limited window of opportunity to intervene to prevent undernutrition and mitigate its long-term health impacts (8) (9) (10) . Sensitive prognostic markers are needed that can detect the subclinical precursors to later deviations from healthy growth while being minimally invasive and permitting frequent monitoring (6, 8, 11, 12) . Because the luminal histopathology characteristic of EE can only be diagnosed by intestinal biopsy, an invasive, technically demanding procedure that is ethically and logistically unsuitable for routine screening, attention has turned to surrogate measures (4, 6, 13) . Numerous analytes detectable in blood, stool, and urine have been proposed as potential biomarkers of the processes underlying EE; however, to our knowledge, their predictive potential has yet to be systematically explored because of methodologic challenges (4, (14) (15) (16) .
We aimed to present a theoretical framework and methodologic approach for assessing the prognostic potential of biomarkers of EE as predictors of subsequent statural growth trajectories during infancy. To explore effects over varying lag lengths, we used data on the fecal concentrations of 3 candidate biomarkers for EE: myeloperoxidase and neopterin (indicators of inflammation) and a-1-antitrypsin (AAT) (indicator of intestinal permeability). We hope this approach can be used by those monitoring biomarkers and infant growth and applied to novel and emerging biomarkers as they become more feasible and affordable to track.
METHODS

Study population
We analyzed data from the Peruvian site of the MAL-ED (Interactions of Malnutrition and Enteric Infections: Consequences for Child Health and Development) project, a network of institutions that has recruited and monitored birth cohorts at 8 locations in different low-and middle-income countries. MAL-ED uses standardized surveillance protocols and assays to collect data on infectious disease incidence, nutritional and anthropometric outcomes, cognitive development, and biological markers (5) . The Peruvian cohort consisted of 303 infants enrolled between December 2009 and February 2012 from a peri-urban community located in the country's forested interior 15 km from the city of Iquitos and on a tributary of the Amazon River, a study setting that has been described in detail elsewhere (17) . Selection and enrollment of each child took place within 17 d of birth according to eligibility and exclusion criteria that have also been outlined elsewhere (5) (Supplemental Figure 1) . Daily data on morbidity, care seeking, and infant feeding were ascertained by caregiver report from twice-weekly household visits, whereas anthropometric and clinical data were collected during monthly assessments (5) . Prior written informed consent from a parent or guardian was a prerequisite for all participants' inclusion in the study. Study staff read the consent form to the caregiver, and then a copy was left in their possession. Ethical approval was given by the Johns Hopkins Institutional Review Board as well as from the partner organization, PRISMA Benefit Association, in Iquitos, Peru.
Outcome variable
The outcome of interest in this study was the child's lengthfor-age z score (LAZ), a widely used measure of nutritional status and attained statural growth and a stable sentinel indicator of physiologic insults that has well-documented associations with overall health, adult economic performance, and cognitive potential (12, 18, 19) . LAZs were calculated with the use of WHO Anthro version 3.2.2 and represent the number of SDs the child's stature lies from the mean in the distribution of a healthy reference population, accounting for age, sex, edema status, and stature measure (20) . Infants' lengths were measured on marked platforms with a sliding footboard. Rigorous quality control measures were implemented and have been described elsewhere (19) . LAZ was treated as a continuous variable rather than dichotomized to minimize the loss of information, maximize the statistical power to detect an association, preserve the variation in the outcome, and avoid residual confounding (21) .
Exposure variables
The primary exposure variables were age and the 3 timevarying candidate fecal markers of EE: myeloperoxidase, neopterin, and AAT. These biomarkers were measured with the use of ELISA tests on stool samples collected from the infants at monthly intervals from birth to 12 mo of age and quarterly from 12 to 36 mo of age. In addition to routine monthly collections, some stool samples were collected between scheduled assessments on the days on which the child's caregiver reported that the child had experienced a diarrheal episode (5) . The samples were collected by fieldworkers who stored them for processing at 2708C without fixative (12) . The assays were run on the samples locally at the MAL-ED site laboratory per the instructions on the package inserts at initial dilutions of 1:500 ng/mL for both myeloperoxidase (ALPCO) and AAT (BioVendor) and 1:1000 nmol/L for neopterin (GenWay Biotech). If the calculated values were found to be out of the range of the standard curve for any of the assays, the samples were run again at a 2-fold higher or lower concentration (as appropriate) (12) . Stool samples were excluded from the analysis if they were collected 1) during or #2 d after a diarrheal episode had been reported (defined from daily household surveillance visits as 3 semiliquid stools in a 24-h period separated by $2 diarrhea-free days) or 2) alongside urine samples obtained for a routine lactulose:mannitol ratio test of intestinal permeability (5, 8) . This was to ensure that the analysis was restricted to markers obtained from samples of suitable consistency to avoid overly diluting the biomarker concentration. They were also excluded if they were recollections of an initial sample that was inadequate for testing but were collected .24 h after the initial sample. Because the distributions of the 3 biomarker measures were highly skewed with a small number of very high outlying values, the log 2 -transformed biomarker values were used instead of the crude concentrations so that the exposure measures were more normally distributed and the effect measures derived could be interpreted as those incurred by 2-fold increments in the marker concentration.
The child's age in months at the time of outcome ascertainment (anthropometric assessment) was treated as the time metric for the analysis and included in the model as a predictor. The relation between age and statural growth during infancy follows a nonlinear curved trajectory ( Figure 1 ). There is a large body of literature relating to methods for characterizing growth curves with the use of parametric models. One of the most flexible approaches and one that allows for the estimation of random effects is to incorporate polynomial functions of the age metric as additional terms in the model (19, 22) . For this analysis, quadratic and cubic terms for age (age 2 and age 3 ) were included as second-and third-degree polynomials.
Potential confounders
The analysis was adjusted for the following covariates:
Calendar time: To adjust for potential secular trends and effects that might have influenced the values for both the exposures and outcome over the course of follow-up, calendar time in continuous months was added to the model and centered on the midpoint between the earliest and latest observation in the dataset. Seasonality: Biomarker concentrations vary seasonally (23) , and nutritional status may also be subject to fluctuations over an annual cycle. To adjust for the potentially confounding effects of these variables, Fourier-series sine and cosine functions were added as terms in the model (see Equation  1 in the Supplemental Material online) (24, 25) . Sex: Although LAZ was calculated separately for males and females, the infants' sexes were included to adjust for potential residual confounding. Birth weight: The child's weight in kilograms at birth was included in the model as a continuous time-fixed variable and centered at the sample mean. Maternal height: The mother's height in centimeters was included as a continuous time-fixed variable centered on the sample mean to adjust for inherited variation in stature. Stool consistency: The concentrations of analytes may be diluted in samples from stools that are of a soft or watery consistency (8) . Numerous samples were excluded from the data set because they were collected soon after a diarrheal episode or lactulose:mannitol ratio test. Among samples that did not meet this exclusion criterion, the consistency of each stool sample, as classified by the fieldworkers, was included in the model as an ordinal time-varying variable with formed stools as the reference category and soft and liquid or watery stools as comparison categories. Infant feeding: Breastfeeding and the timing of the introduction of complementary foods and weaning are related to both nutritional and immune status as measured by the 3 biomarkers (23) . Daily breastfeeding status and the introduction of complementary food to the infants' diets were ascertained by a caregiver report during home visits (5) and categorized in accordance with standard definitions described elsewhere in the literature (26) . Subjects' feeding status on the day before the biomarker measure was included in the analysis as an ordinal time-varying predictor with partially breastfed (the category with the largest number of observations) treated as the reference category and exclusively breastfed, predominantly breastfed, and not breastfed as comparison categories.
Statistics
For each candidate fecal biomarker of EE, we constructed a linear mixed-effects model to estimate the mean LAZ as a function of age and the biomarker after adjusting for calendar time, seasonality, and the a priori-selected infant and mother confounders. The relation between mean LAZ and age was modeled as a cubic function (main terms of age, age 2 , and age 3 ) and was allowed to vary by the concentration of the biomarker by including the main effect of the biomarker and interactions of the age terms and the biomarker. Product interaction terms for the differential effect of age in the presence of increased biomarker concentrations were calculated by multiplying the log 2 biomarker values by each of the 3 age variables (linear, quadratic, and cubic) and were included in the model to capture potential-effect measure modification. The covariates entered the model as main terms with the exception of seasonality, which was modeled with the use of Fourier-series sine and cosine functions (24, 25) . To account for the correlation of LAZs within a child over time, the model included a random intercept and random slopes for the linear and quadratic age terms; these random effects were allowed to be correlated with one another. The within-child residual LAZs were assumed to be independent. Because we interested in predicting future deceleration in statural growth, the biomarker values were initially lagged by 3 mo so that the analysis assessed the association between the children's LAZ at month of age j and the biomarker measured at age j-3. This lagging was to establish the temporal order of the association, an important methodologic consideration in exploring the complex hypothesized relation between infection, immune response, and nutritional status, which is both bidirectional and acts over a causal pathway that is not instantaneous but cumulative over the course of many weeks and months of life (12) . A lag time of 3 mo was considered to be of clinical significance because it allows a sufficient window for nutritional intervention. The models were also rerun with increasing lag lengths from 0 to 6 mo to compare the associations with growth over increasing age windows. A mathematical representation of the model is presented in the Supplemental Material.
Likelihood ratio tests were used to determine 1) whether the biomarkers modified the association between the mean LAZ and age by comparing our model to a simpler model that dropped the interaction terms between age and the biomarker and 2) whether the biomarkers contributed any information to describe the mean LAZ by comparing our model to a simpler model that dropped all biomarker terms (main effect and interactions). R 2 statistics were calculated to estimate the proportion of the total variation in LAZ that the model explained (27) . Partial R 2 statistics were calculated to estimate the proportion of the total variation in LAZ that is explained solely by the biomarker and its interaction with age. This partial R 2 calculation used the sum of squares error of our full model and that of the simpler null model that excluded all biomarker terms (main effect and terms for interactions) (27) . The partial R 2 may be an optimistic estimate because the model was fitted and the R 2 computed from the same data.
Standard regression diagnostics, including added variable plots and observed compared with expected plots, were used to assess the fit of our models to the observed data. To confirm that the polynomial approach accurately characterized the shape of the growth curves, results were compared with similar models that used restricted cubic splines with 5 knot locations determined by percentiles. Changes in the direction of the association over age were verified by running cross-sectional regressions at each month of age and comparing the sign of the main coefficient. Finally, the model was rerun with all 3 biomarkers, and their interaction terms were included together to determine whether any of their significance levels changed in the presence of the others.
At 36 mo of age, anthropometric data were missing for 43.6% of the initial sample, whereas 37.0% of the subjects had some intermittent outcome data. LAZ was unavailable for $1 mo of age but available for a later assessment. Attrition from the study was rarely because of mortality and is instead explained by the temporary or intermittent outmigration of families from the study site (numerous participants returned to the study after having been lost to follow-up for many months) (28) . Attrition and intermittent missingness in the outcome were explored to characterize the pattern of dropout. We explored patterns of dropout and missing data by comparing the LAZ trajectories among infants that dropped out of the study with those that did not and estimating the difference in the mean LAZ among those with missing outcomes at the next monthly assessment and the rest of the sample at various time points. We assumed that the data were missing at random, and our analyses were valid under this assumption because the use of a mixed model (a likelihoodbased approach) can adequately account for such missingness patterns (22, 29) . Analyses were conducted with the use of Stata version 13.1 (StataCorp) (30) . Table 1 presents the demographic, nutritional, anthropometric, and clinical characteristics of the study population. Although anthropometric data were collected from children aged #5 y, the mean age at censoring (either administrative or because of attrition) was 37 mo and varied considerably because of the staggered enrollment. The crude (untransformed) biomarker concentrations exhibited a high level of both within-and between-subject variability and had overall SDs that were larger than the mean values, a result of their distribution being heavily skewed toward higher values. This variability and skewing was greatly reduced when they were log 2 -transformed. A larger proportion of stool samples was of soft consistency rather than formed (67.0% compared with 26.4%), a fact that may have introduced measurement error into the calculation of the biomarker concentrations. Liquid and watery stools made up just 6.6% of the samples, probably because samples collected soon after a diarrheal episode were excluded from the data set. Approximately half of the stool samples were taken from infants who had been partially breastfed the previous day, whereas the remaining half was divided roughly equally between the feeding categories. Data on child's birth weight and mother's height were fairly complete (,5% missing). The slightly higher proportion of males in this birth cohort is consistent with the natural human sex ratio at birth. Figure 1 plots the mean LAZ by month of age for the sample, demonstrating that mean nutritional status in this study site declined sharply over the first 19 mo of life and then steadily increased to 5 y but without regaining its initial value. This is a fairly typical pattern for a Latin American context and many developing country settings (31) . Figure 2 shows the same trends for each of the 3 biomarkers. The overall pattern for all 3 was of decreasing biomarker concentration over the first 3 y of life. For AAT, this downward trend was roughly linear, whereas for myeloperoxidase and neopterin it was curved convexly, rising in early infancy and then declining steadily after a peak between 6 and 9 mo of age. Table 2 presents the parameter estimates from the linear mixed-effects models that were fit separately for each of the 3 biomarkers with a 3-mo lag. The data strongly support an agedependent association between the biomarker and subsequent LAZ for AAT (likelihood ratio chi-square test: 28.71; P , 0.0001), myeloperoxidase (likelihood ratio chi-square test: 62.79; P , 0.0001), and, to a lesser extent, neopterin (likelihood ratio chi-square test: 13.97; P = 0.0074). Figure 3 plots the growth trajectory predicted by the models for 3 concentration levels of each biomarker (5th, 50th, and 95th percentiles of the overall sample distribution), with 95% CIs from 3 to 39 mo of age accounting for interaction with age but holding all other covariates constant. This figure illustrates that both AAT and myeloperoxidase interacted strongly with age and in a similar way, such that the magnitude, and possibly even the direction of the effect, varied considerably over the first 3 y of life. Both markers predicted wide differences in LAZs between the 2 extremes of their distributions at 10 and 27-29 mo of age; the myeloperoxidase model had the largest difference during the former period, and AAT had the largest difference during the latter period. The neopterin model did not predict the same differences with age. Instead, the estimated trajectories across the distribution of the biomarker were similar, only converging for a brief period between w24 and 30 mo of age. These patterns were broadly similar to those predicted by the cubic spline models that were run as a sensitivity analysis (data not shown). The CIs for the curves predicted by the 2 extreme values overlapped throughout the 3 y for all 3 biomarkers, indicating a lack of evidence that these predictions reflected a true difference in growth for these values of the markers. When crosssectional linear regression models were run at various different age points (data not shown), their results broadly confirmed the direction of association, although individually, few of these models attained any degree of statistical significance.
RESULTS
There was no statistically significant association between calendar time and the outcome in any of the models, suggesting the absence of any secular trend in infant nutritional status in the study site over the follow-up period. In all 3 models, the coefficient estimate for the sine function attained some degree of statistical significance, evidence that trends in nutritional status fluctuated seasonally, peaking in the first half of the year. This may be because of changes in the availability or market price of certain foods over annual cycles or to seasonally varying climatic drivers of diarrheal disease risk (such as fluctuations in the river levels that affect sanitation conditions). A likelihood ratio test for the inclusion of the seasonality terms in the model showed that they significantly improved the model for all 3 biomarkers. In all 3 models, females had an estimated LAZ that was statistically significantly higher than males over the follow-up period by a quantity that varied from 0.27 (myeloperoxidase) to 0.31 (AAT), indicating that the adjustment by sex of the LAZs failed to eliminate residual confounding by sex. Each 1-kg increment in birth weight above the mean was statistically significantly associated with a 0.90-0.95 increase in LAZ. The equivalent estimate for a 1-cm increase in mother's height was a highly statistically significant 0.03 increase. Children whose stool samples were soft experienced a small (0.05) additional decline in LAZ over the subsequent 3 mo relative to those who contributed formed stool samples at the same age. No equivalent difference was detected for liquid or watery stool samples. This may be because they made up too small a proportion of the data to detect a difference or because higher biomarker concentrations in diarrheal stools (which are typically more liquid) offset their greater dilution (23) . A child having been predominantly breastfed on the day before the stool sample was taken was associated with a small but statistically significant decrease in LAZ over the following 3 mo compared with those who had been partially breastfed, but there was no equivalent statistically significant difference either for those who were exclusively breastfed or those who received no breast milk at all. Approximately 90% of the observed variations in LAZs was explained by this combination of explanatory variables in all 3 cases. Although this proportion might seem high for such a complex and variable biological process as growth, it is worth bearing in mind that the effects of age on LAZ were modeled quite closely with the use of the polynomial terms and subjectspecific random effects, which together capture a large proportion of the within-subject variance. The inclusion of basic baseline characteristics of the child such as birth weight, sex, and mother's height may have ensured that a high proportion of betweensubject variation was also captured. However, the partial R 2 for the combined contribution of the biomarkers to the explanatory capability of the models was small for all biomarkers ( Table 2 ). Myeloperoxidase had the highest partial R 2 , explaining 2.4% of the variability in LAZ 3 mo later. The equivalent statistic for neopterin was just 0.2%, and for AAT it was 0.7%, despite the fact that this latter biomarker was also highly significantly associated with the outcome. Table 3 compares the likelihood ratio test and partial R 2 statistics for the 3 biomarkers over increasing lag lengths from 0 to 6 mo. It also gives the largest difference in LAZ that the model predicted between the 5th and 95th percentile of the log 2 biomarker from 3-30 mo of age and the month of age at which this largest difference occurred (an indicator of the clinical significance of the association). For all 3 markers, the statistical significance of the likelihood ratio test and the R 2 statistic was highest for a 1-or 2-mo lag and generally decreased with each increase in lag length (except for a 6-mo lag). The largest proportion of the variance explained by any biomarker (2.8%) was by myeloperoxidase over a 2-and a 4-mo lag; the former model also predicted the largest difference in LAZ between the 5th and 95th percentile (0.25 at 8 mo of age). AAT with a 1-mo lag predicted a clinically significant 0.24 difference in LAZ at 27 mo of age; however, the partial R 2 for the biomarker in that model was much smaller than for myeloperoxidase. Even without applying a lag (the 0-mo model), myeloperoxidase was still highly significantly associated with the outcome, a fact that may be explained by the high within-subject correlation of LAZ from one age to the next.
When all 3 biomarkers and the terms for their interaction with age were included in a single multilevel mixed-effects linear regression model along with the other covariates (a total of 12 biomarker terms), all terms for AAT and neopterin lost all statistical significance, whereas the terms for myeloperoxidase remained highly statistically significant. The likelihood ratio test statistics for each biomarker (compared with a null model in which that biomarker was excluded but the terms for the other 2 were kept) were just 6.52 (P = 0.163) for AAT and 4.22 (P = 0.377) for neopterin but 62.34 (P , 0.001) for myeloperoxidase. This indicates that myeloperoxidase remained highly significantly associated with the outcome in the presence of the other biomarkers, whereas the AAT terms lost all significance and the lack of association between neopterin and LAZ remained.
DISCUSSION
There are numerous methodologic challenges in assessing biomarkers of EE as predictors of subsequent statural growth.
The statistical significance of a detected association is no guarantee of clinical significance because any single biomarker is likely to explain a very small proportion of the overall variance in such a multifarious outcome. Furthermore, as shown herein, the relation between immune response and longer-term enteropathy is not linear. Some degree of self-limiting inflammatory response is protective against enteric pathogens, and the duration over which prolonged inflammation becomes pathologic and the balance between injury and insult may vary with age and other factors (11) .
In this study, we piloted a methodologic framework for modeling infant growth with the aim of assessing the prognostic performance of EE biomarkers. By including polynomial terms for age, random effects, baseline characteristics that can be measured affordably, caregiver-reported data on feeding status, and coefficients for calendar time and seasonality, we were able to explain .85% of the variance in LAZs. The biomarkers could then be assessed based on the additional proportion of the variance that they were able to explain as well as on the statistical significance of their effect. All 3 biomarkers were highly significantly associated with the outcome for $1 lag length-results that are consistent with findings from a study in Northeast Brazil for myeloperoxidase and AAT (32) and in Gambia for neopterin (33) . In addition, within each individual biomarker, this statistical significance seemed to correlate with the partial R 2 . This builds on the work of Kosek et al. (8) , who analyzed an earlier subset of stools from all 8 MAL-ED sites and demonstrated a 1-U increase in an aggregated index of these 3 markers to be statistically significantly predictive of a 0.47 decrease in LAZ, an approach that has since been applied to similar data from Bangladesh (34). However, there was considerable difference in the partial R 2 between biomarkers, and myeloperoxidase and its interactions consistently explained a proportion of the variance in LAZ that, although small compared with the overall model, was an order of magnitude higher than that of the other 2 biomarkers. Furthermore, the results presented herein serve as a reminder that the statistical significance of a biomarker and its ability to explain variance in the outcome does not necessarily translate into clinical significance of the association. One of the largest differences in LAZ between the 5th and 95th percentile of the biomarker distribution predicted by any model was for AAT over 1 mo (0.24). However, the partial R 2 and likelihood ratio test statistic for this biomarker and its interactions was small compared with myeloperoxidase, which predicted a similar difference over a 2-mo lag. Furthermore, because of the high within-subject variability exhibited by all 3 of these biomarkers and the small effect sizes, their clinical potential as prognostic markers of future nutritional status is likely to be somewhat limited. The predicted growth trajectories shown in Figure 3 are abstractions to some extent because it would be rare for any given infant to remain at the same percentile of the biomarker distribution from one assessment to the next, much less over the entire course of the follow-up.
These considerations have implications for those monitoring both existing and future novel biomarkers for interventions. The explanatory power of any given analyte is likely to be small within a model that includes much more strongly predictive covariates such as age and sex. As existing biomarkers become more routinely monitored and new ones become available, they will need to be judged by multiple standards: their additive explanatory power relative to other covariates as well as their clinical and statistical significance. By these standards, myeloperoxidase performed fairly promisingly as a prognostic marker of undernutrition because a partial R 2 of 2.8% is large for a single enzyme, and this measure remained high across increasing lag lengths. Furthermore, myeloperoxidase's statistical association with nutritional status retained its strong significance even when adjusting for the other 2 biomarkers. Future research should focus on this marker's ability to predict nutritional outcomes over a 2-mo window during the first year of life with the use of data from other populations. AAT may yet show some limited promise as a clinical marker, particularly late in the second and early in the third year of life, during which it seems to predict its widest difference in growth trajectories.
We have also demonstrated that the associations identified herein had a complex interaction with age. This age dependence was broadly intelligible within the EE paradigm that emphasizes the dynamic nature of the relation between infection, immunity, and nutrition during infancy. We speculate that, although some degree of intestinal inflammation may be beneficial for fighting off enteric infections that might otherwise hinder growth, chronic inflammation persisting into later infancy may eventually become pernicious, a delicate balance that may shift as a child ages. The finding that the direction of the relation seems to reverse at least once over the first 3 y of life, although not without precedent (35) , should be interpreted with caution and in light of the largely overlapping CIs for the predicted trajectories. Further studies with larger sample sizes will be needed before this can be confirmed. The finding that the association between AAT and LAZ loses significance when myeloperoxidase is present in the model also merits further attention. The permeability of the intestine may be a more distal determinant on the pathway between pathogen exposure and undernutrition, mediated by the proximal factor of inflammation. If this is the case, it would suggest that nutrient loss because of the extravasion of serum proteins may play a secondary role in EE compared with the primary factor of the diversion of nutrients away from growth toward the mounting of inflammatory immune responses to infections. However, the relative roles of these 2 pathways may themselves vary with age. There are numerous ways in which this methodology could be adapted to address other exposures or different outcome definitions. Change in nutritional status could be defined instead as the change in LAZ over a given window (8, 14) , as a binary indicator of stunting, or by exposure to wasting-either as a time-varying weight-for-age z score or by total exposure calculated as the AUC. Other covariates that could be considered for inclusion in similar models include diarrheal episodes (which herein were adjusted for by excluding diarrheal stools and adjusting for the consistency of the remaining samples), presence of infection with enteric pathogens, or dietary intake. Studies that involve large panels of analytes could proceed by applying machine-learning methods to identify the optimal subset, which can then be treated as exposures in a model such as the one presented herein.
